Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Bristol-Myers Squibb ($BMY) extended its portfolio by securing exclusive worldwide rights to PsiOxus Therapeutics' NG-348, a preclinical stage "armed" oncolytic virus which may potentially be used to treat solid tumors. The agreement calls for $50M upfront payment to PsiOxus. The company is also entitled to receive up to $886M in milestones and royalties on commercial sales.
Bristol-Myers Squibb will be responsible for funding preclinical development of NG-348. The drug candidate dictates T-Cell immune response in the tumor microenvironment. Both the firms had collaborated earlier this year for PsiOxus' systemically administered "unarmed" oncolytic adenovirus therapeutic, enadenotucirev.

DexCom ($DXCM) announced that its G5 Mobile CGM system has received the approval from the US Food and Drug Administration (FDA). This system has been recognized as the first and only continuous glucose monitoring system that can be used to make daily diabetes treatment decisions without finger pricking.
The system has received ‘non-adjunctive’ indication which extends the scope of the system to replace finger stick glucose testing for diabetes treatment decisions. This indication expands the potential market for the system. The company stock reacted positively to the news and ended its previous trading session at $63.56, after touching the day high of $67.80.


• Parnell Pharmaceutical Holdings ($PARN) announced that its intends to voluntarily delist from the Nasdaq Global market. The delisting will be effective from December 31. Shares will be quoted on the OTC Pink Open Market thereafter.
• Align Technology ($ALGN) lost its appeal of two adverse rulings in Germany seeking to invalidate two patents covering orthodontic treatment Invisalign. The company had sued privately held Hamm, Germany-based Ortho Caps GmbH in 2011 accusing it of infringing on five patents covering Invisalign.

• Sarepta Therapeutics' ($SRPT) announced that The European Medicines Agency has accepted the company’s Marketing Authorization Application seeking conditional approval of eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping for review.
• Ironwood Pharmaceuticals ($IRWD) announced that its LINZESS (linaclotide) drug candidate for the treatment of adults with irritable bowel syndrome has been approved by the Japanese Ministry of Health, Labor and Welfare.

• Agilent ($A) enters into an agreement to acquire Multiplicom N.V. in a €68M cash deal. The Belgian firm develops and markets molecular diagnostic assays in cancer, cardiology and certain genetic disorders for helping develop personalized medicine.
• Soligenix ($SNGX) has extended its collaboration with German biotech IDT Biologika for the manufacture of RiVax, its proprietary heat-stable ricin toxin vaccine. The parties did not disclose financial terms.

• Recro Pharma ($REPH) received initial rating of Overweight from Piper Jaffray. The stock price target has been set at $12.
• Tonix Pharma ($TNXP) receives Hold rating from Oppenheimer.

Gainers (% price change) Last Trade Change Mkt Cap
ACADIA Pharmaceuticals
28.56 +3.13 (12.31%) 3.39B
Curis, Inc.
3.42 +0.36 (11.76%) 493.58M
China Cord Blood Corp
4.91 +0.49 (11.09%) 355.56M
Derma Sciences Inc
5.25 +0.35 (7.14%) 145.45M
Clovis Oncology Inc
42.49 +2.01 (4.97%) 1.78B
Losers (% price change)
Sucampo Pharmaceuticals
13.27 -3.43 (-20.51%) 645.19M
MediciNova, Inc.
6.88 -0.48 (-6.52%) 242.55M
Cerus Corporation
4.55 -0.29 (-5.99%) 463.12M
Sangamo Biosciences, Inc.
3.25 -0.20 (-5.80%) 216.95M
Dynavax Tech. Corp.
4.20 -0.20 (-4.55%) 161.82M
Most Actives (dollar volume)
Pfizer Inc.
32.85 +0.02 (0.06%) 199.28B
Biogen Inc
285.41 +6.64 (2.38%) 60.44B
Johnson & Johnson
115.66 -0.36 (-0.31%) 315.04B
Gilead Sciences, Inc.
74.05 -0.35 (-0.47%) 97.95B
Merck & Co., Inc.
60.50 -0.64 (-1.05%) 163.33B